Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
NCT07107841
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Androgenic Alopecia
- Alopecia
- Baldness
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Acorn Biolabs Inc.
- Last updated on ClinicalTrials.gov
- February 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Ziering Medical · West Hollywood, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.